系统性硬化症患者的COVID-19疫苗接种与感染:硬皮病患者为中心干预网络(SPIN)队列研究
该研究基于SPIN队列,于2021年4-5月和2022年6-7月两次调查系统性硬化症(SSc)患者的COVID-19疫苗接种率、不良事件、围接种期免疫抑制剂管理、疫苗犹豫及感染情况。2022年数据中489名参与者有437名(89%)完成基础系列和至少一剂加强针;全部1033名参与者中960名(93%)至少接种一剂。最常见不良事件为手臂酸痛和乏力,无严重不良反应报告。
要点
- 2022年489名SSc参与者中437名(89%)完成基础疫苗系列和至少一剂加强针。
- 接种后不良事件以手臂酸痛和乏力为主,无严重不良反应报告。
- 2022年489名参与者中172名(35%)报告至少一次COVID-19感染史。
核心结论
- 研究中大多数SSc患者完成全程接种,且多数在基础及加强接种后继续使用甲氨蝶呤或霉酚酸酯。
- 疫苗犹豫者中超过半数担心疫苗相关SSc flare,但已接种者中报告此情况者少。
- 这些数据可能有助于为SSc患者提供关于COVID-19疫苗安全性和结局的咨询。
研究设计与样本
- SPIN队列研究,于2021年4-5月和2022年6-7月对参与者进行COVID-19疫苗接种和感染调查。
- 544名参与者仅完成2021年调查,101名仅完成2022年调查,388名完成两次调查。
- 基础疫苗系列按每种COVID-19疫苗的标准定义,额外接种视为加强剂量;完全接种定义为完成基础系列和至少一剂加强针。
主要发现
- 2022年数据489名参与者中437名(89%)接受基础疫苗和加强针;全部1033名参与者中960名(93%)至少接种一剂。
- 至少一次不良事件报告率:第一剂后34%(330/960)、第二剂后48%(314/657)、加强针后34%(147/437),主要为手臂酸痛和乏力,无严重不良反应报告。
- SSc症状加重报告率:第一剂后6%(53/960)、第二剂后6%(39/657)、加强针后4%(17/437)。
- 使用甲氨蝶呤或霉酚酸酯(包括Cellcept或Myfortic)者中,第一剂时266名中34名(13%)报告暂时停药或减量,第二剂时215名中32名(15%),加强针时148名中28名(19%)。
- 2022年52名未完成基础系列和加强针者中29名(56%)报告担心疫苗相关SSc flare;489名2022年参与者中172名(35%)报告至少一次COVID-19感染史,其中114名(66%)发生在至少接受基础疫苗系列后;初始感染中9名(5%)无症状、66名(38%)轻症、82名(48%)中度症状、15名(9%)需住院。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: We previously surveyed adults with systemic sclerosis (SSc) regarding COVID-19 vaccination in April-May 2021. The objective of the present study was to update through June-July 2022 and assess self-reported (1) COVID-19 vaccination rates, including boosters; (2) vaccine-related adverse events; (3) peri‑vaccination immunosuppressive medication management; (4) vaccine hesitancy; and (5) prevalence and severity of COVID-19 infections. METHODS: In April-May 2021 and June-July 2022, SPIN Cohort participants completed surveys on COVID-19 vaccination and infection. Primary vaccine series was defined according to the standard for each COVID-19 vaccine; additional vaccine administrations were considered booster doses. Fully vaccinated was defined as having completed a primary vaccine series and at least one booster dose. RESULTS: 544 participants completed the 2021 survey only, 101 the 2022 survey only, and 388 both surveys. Among 489 participants with 2022 data, 437 (89 %) had received both primary and booster vaccines. Among all 1,033 participants, 960 (93 %) received at least one dose. At least one adverse reaction was reported by 34 % (330 of 960 participants) following first, 48 % (314 of 657 participants) following second, and 34 % (147 of 437 participants) following booster vaccine doses (primarily sore arm and fatigue); no severe adverse reactions were reported. SSc symptom worsening was reported in 6 % (53 of 960) after the first, 6 % after the second (39 of 657), and 4 % (17 of 437) after the booster dose. Of participants taking methotrexate or mycophenolate (including Cellcept or Myfortic), 34 of 266 (13 %) reported that they temporarily stopped or decreased their medication at the first dose, 32 of 215 (15 %) at the second dose, and 28 of 148 (19 %) for booster vaccination. Of 52 individuals not fully vaccinated with primary and booster doses in 2022, 29 (56 %) reported worry about vaccine related SSc flares. 172 of 489 (35 %) 2022 participants reported a history of at least one COVID-19 infection; 114 (66 %) occurred after receiving at least a primary vaccine series. Among initial COVID-19 infections, 9 (5 %) were asymptomatic, 66 (38 %) involved mild symptoms, 82 (48 %) moderate symptoms, and 15 (9 %) required hospitalization. CONCLUSION: Most people with SSc in the study were fully vaccinated, and most continued their methotrexate or mycophenolate post-primary and booster vaccinations. Over half of vaccine-hesitant participants were concerned regarding risk of SSc flare; however, few vaccinated participants reported this. These data may be useful for counselling people with SSc regarding COVID-19 vaccine safety and outcomes.
引用
- Lakin KS, Wu Y, Gordon JK, et al. COVID-19 vaccinations and infections among individuals with systemic sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Semin Arthritis Rheum. 2024. PMID: 38851172. doi:10.1016/j.semarthrit.2024.152453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。